首页> 外文期刊>Peritoneal dialysis international: Journal of the International Society for Peritoneal Dialysis >Effects Of peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates.
【24h】

Effects Of peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates.

机译:GDP较低的腹膜透析溶液对腹膜炎和出口部位感染率的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Peritoneal dialysis (PD) solutions sterilized at a low pH level contain only minimal amounts of glucose degradation products (GDPs). The latter are known to have an adverse effect on the peritoneal membrane. The present study retrospectively analyzes the effects on the incidences of peritonitis and exit-site infections. MATERIALS AND METHODS: Data concerning the frequency of peritonitis and exit-site infections for 120 patients treated with PD were collected. Before 2000, 67 of these patients received conventional dialysates and from 2000 on, 53 patients were treated with the new dialysis fluids. Furthermore, a correlation between the incidence of infections and the duration of treatment with dialysis was established. RESULTS: It was observed that the use of dialysis solutions low in GDPs resulted in significantly lower rates of peritonitis (p = 0.002) and exit-site infections (p = 0.02). When using the new treatment, peritonitis occurred, on average, after 48 months of treatment and exit-site infections after 34 months of treatment. DISCUSSION: The result supports the hypothesis that the use of the new, biocompatible, PD solutions contributes to considerable reduction in the rates of peritonitis and exit-site infections. As it is not expected that randomized prospective studies will be conducted in the future, further observational studies should be carried out in order to affirm the observed tendencies.
机译:背景:在低pH值下灭菌的腹膜透析(PD)溶液仅包含极少量的葡萄糖降解产物(GDPs)。已知后者对腹膜有不利影响。本研究回顾性分析对腹膜炎和出口部位感染的发生率的影响。材料与方法:收集有关120例接受PD治疗的患者的腹膜炎发生频率和出口感染的数据。在2000年之前,其中67位患者接受了常规透析液;从2000年开始,有53位患者接受了新的透析液治疗。此外,建立了感染率与透析治疗时间之间的相关性。结果:观察到使用低GDP的透析液可显着降低腹膜炎的发生率(p = 0.002)和出院部位感染(p = 0.02)。使用新疗法时,平均腹膜炎发生在治疗48个月后,而发生出口感染则在治疗34个月后。讨论:该结果支持以下假设:使用新的生物相容性PD解决方案可显着降低腹膜炎和出口部位感染的发生率。由于预计将来不会进行随机的前瞻性研究,因此应进行进一步的观察性研究以确认观察到的趋势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号